Quimioterapia antineoplásica frente al cáncer de mama en mujeres embarazadasPrevención de Extravasaciones

  1. Raúl de la Puente García 1
  2. Raquel Díez Láiz 1
  3. Ana María Sahagún Prieto 1
  4. María Nélida Fernández Martínez 1
  5. María José Díez Liébana 1
  6. Matilde Sierra Vega 1
  7. Juan José García Vieitez 1
  8. Cristina López Cadenas 1
  9. Salvador Postigo Mota coord. 2
  1. 1 Área de Farmacología. Departamento de Ciencias Biomédicas. Campus Vegazana, Universidad de León.
  2. 2 Facultad de Medicina. Universidad de Extremadura.
Journal:
Revista ROL de enfermería

ISSN: 0210-5020

Year of publication: 2023

Issue Title: Abordaje y prevención de las lesiones cutáneas

Volume: 46

Issue: 5

Pages: 10-18

Type: Article

More publications in: Revista ROL de enfermería

Metrics

Índice Dialnet de Revistas

(Indicator corresponding to the last year available on this portal, year 2022)
  • Year 2022
  • Journal Impact: 0.090
  • Field: ENFERMERÍA Quartile: C2 Rank in field: 15/43

Journal Citation Indicator (JCI)

(Indicator corresponding to the last year available on this portal, year 2022)
  • Year 2022
  • Journal Citation Indicator (JCI): 0.02
  • Best Quartile: Q4
  • Area: NURSING Quartile: Q4 Rank in area: 190/191

Abstract

Gestational cancer can be defined as cancer that occurs during pregnancy or within the first year after delivery. Among them, breast cancer occupies the first place in frequency with an increasing incidence that is situated at about 1 per 3.000 pregnant women. In pregnant women, the diagnosis of cancer represents a challenge in terms of clinical management, due to the need to guarantee maternal safety and ensure the state of pregnancy. This tends to be delayed and detected at later stages because the associated symptoms can be easily related to a normal pregnancy situation. Pregnant women diagnosed with cancer should be evaluated by a multidisciplinary tumor team, specialized in cancer during pregnancy. One of the treatments used to address breast cancer is antineoplastic chemotherapy, which must be administered in a hospital, taking into account different factors such as the general condition of the patient, possible previous diseases, the type, stage and location of the tumor, as well as the week of gestation in which the woman is. Treatment can be started from week 13-14 of gestation, the most widely used regimens to date are: 3-week cycles of FAC (5-fluorouracil, doxorubicin and cyclophosphamide), FEC (5-fluorouracil, epirubicin and cyclophosphamide), AC (doxorubicin and cyclophosphamide) and EC (epirubicin and cyclophosphamide) or weekly epirubicin as monotherapy. Likewise, the use of taxanes (paclitaxel as a single agent) stands out. The nurse is a fundamental pillar within the multidisciplinary team of tumors, specialized in breast cancer during pregnancy, who will care for and accompany the pregnant woman throughout the disease process. Breast cancer, and more in pregnant women, entails a series of changes in their lives that require different processes of physical, psychological and social adaptation. To facilitate adaptation to breast cancer, the team nurses must take into account all the factors that could affect the pregnant woman in this process and initiate the necessary interventions in early stages. Carrying out a complete nursing assessment favors the detection of real problems and helps prevent the appearance of possible complications. This assessment, together with a Nursing Care Plan in the integrated care process for breast cancer, will improve the quality of life and holistic care of pregnant cancer patients. Likewise, nurses play a very important role in the prevention and treatment of the possible adverse effects of oncological therapy, with extravasation being one of the most serious complications associated with the administration of these drugs, which can cause chronic and irreversible damage.

Bibliographic References

  • Asociación Española contra el Cáncer. Tipos de cáncer [Internet]. 2016 [cited 2023 Feb 4]. Available from: https://www.contraelcancer.es/es/todo-sobre-cancer/tipos-cancer
  • Eibye, S.; Krüger Kjaer, S.; Mellemkjaer L. Incidence of pregnancy-associated cancer in Denmark, 1977-2006. Obs Gynecol. 2013;122(3):608–17.
  • Parazzini, F.; Franchi, M.; Tavani, A.; Negri, E.; Peccatori FA. Frequency of Pregnancy Related Cancer: A Population Based Linkage Study in Lombardy, Italy. Int J Gynecol Cancer. 2017;27(3):613–9.
  • De Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19(3):337–46.
  • Instituto Nacional del Cáncer. Naturaleza del cáncer [Internet]. [cited 2023 Feb 15]. Available from: https://www.cancer.gov/espanol/cancer/naturaleza/que-es
  • Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al. Multidisciplinary consensus on cancer management during pregnancy. Clin Transl Oncol [Internet]. 2021;23(6):1054–66. Available from: https://doi.org/10.1007/s12094-020-02491-8
  • Falkenberry S. Breast cancer in pregnancy. Obs Gynecol Clin North Am. 2002;29(1):225–32.
  • Monleón J, Monleón LGFJ. Cáncer y gestación. 2006;33(3):80–92.
  • Santos JA. Cáncer de mama: estudio desde la práctica del cuidado de enfermería. Machala 2015. Cumbres. 2018;4(1):09–21.
  • Valle I, Tramalloni D, Bragazzi NL. Cancer prevention: State of the art and future prospects. J Prev Med Hyg. 2015;56(1):21–7.
  • Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, et al. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control. 2016;27(4):459–72.
  • Paris I, Di Giorgio D, Carbognin L, Corrado G, Garganese G, Franceschini G, et al. Pregnancy-Associated Breast Cancer: A Multidisciplinary Approach. Clin Breast Cancer [Internet]. 2021;21(1):e120–7. Available from: https://doi.org/10.1016/j.clbc.2020.07.007
  • American Cancer Society. Signos y síntomas del cáncer de seno [Internet]. 2016 [cited 2023 Feb 12]. Available from: https://www.cancer.org/es/cancer/cancer-de-seno/pruebas-de-deteccion-y-deteccion-temprana-del-cancer-de-seno/signos-y-sintomas-del-cancer-de-seno.html
  • Sociedad Española de Oncología Médica. Las cifras de cáncer en España 2022 [Internet]. 2022 [cited 2023 Feb 8]. Available from: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf
  • Boere I, Lok C, Poortmans P, Koppert L, Painter R, vd Heuvel-Eibrink MM, et al. Breast cancer during pregnancy: epidemiology, phenotypes, presentation during pregnancy and therapeutic modalities. Best Pract Res Clin Obstet Gynaecol [Internet]. 2022;82:46–59. Available from: https://doi.org/10.1016/j.bpobgyn.2022.05.001
  • López ICC, Moreno MJV. EstresYAfrontamientoEnPacientesConCancerDeMama [Internet]. Disciplinares de la UCPR. 2007. Available from: https://www.researchgate.net/publication/338750555_Dialnet-EstresYAfrontamientoEnPacientesConCancerDeMama-6093549
  • McCormick, A.; Peterson E. Cancer in Pregnancy. Obs Gynecol Clin North Am. 2018;45(2):187–200.
  • Davison J, Narain S, McEwan A. Cancer in pregnancy. Obstet Gynaecol Reprod Med [Internet]. 2017;27(8):251–5. Available from: http://dx.doi.org/10.1016/j.ogrm.2017.06.003
  • Oehler M.; Wain, G.; Brans A. Gynaecological malignancies in pregnancy: A review. Obs Gynecol. 2003;43(6):414–20.
  • Benedí, J.; Gomez del Rio MA. Fármacos antineoplásicos ( I ). Farm Prof. 2006;20(I).
  • Murphy CG, Mallam D, Stein S, Patil S, Howard J, Sklarin N, et al. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer. 2012;118(13):3254–9.
  • Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B LS. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532–9.
  • Cardonick, Elyce MD; Dougherty, Rebecca MD; Grana, Generosa MD; Gilmandyar, Dzhamlaa MD; Ghaffar, Sadia MD¶; Usmani AM. Breast Cancer During Pregnancy Maternal and Fetal Outcomes. Cancer J. 2010;16(1):76–82.
  • Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, et al. Treatment of breast cancer during pregnancy: An observational study. Lancet Oncol [Internet]. 2012;13(9):887–96. Available from: http://dx.doi.org/10.1016/S1470-2045(12)70261-9
  • Macdonald HR. Pregnancy associated breast cancer. Breast J. 2020;26(1):81–5.
  • Zagouri F, Sergentanis TN, Chrysikos D, Dimitrakakis C, Tsigginou A, Zografos CG, et al. Taxanes for Breast Cancer during Pregnancy: A Systematic Review. Clin Breast Cancer [Internet]. 2013;13(1):16–23. Available from: http://dx.doi.org/10.1016/j.clbc.2012.09.014
  • Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: Case series and review of the literature. Ann Oncol [Internet]. 2012;23(12):3016–23. Available from: https://doi.org/10.1093/annonc/mds170
  • Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, et al. Taxanes for breast cancer during pregnancy: A systematic review. Ann Oncol [Internet]. 2010;21(2):425–6. Available from: https://doi.org/10.1093/annonc/mdp517
  • Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 2016;160(2):347–60.
  • Shachar S, Gallagher K, McGuire K, Zagar TM, Faso A, Muss HB, et al. Multidisciplinary Management of Breast Cancer During Pregnancy. Oncologist. 2018;23(6):746–746.
  • Yildirim N, Bahceci A. Use of pertuzumab and trastuzumab during pregnancy. Anticancer drugs. 2018;29(8):810–3.
  • Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol [Internet]. 2012;23(SUPPL. 7):vii167–73. Available from: http://dx.doi.org/10.1093/annonc/mds294
  • Alfaro-Rubio A, Sanmartín O, Requena C, Llombart B, Botella-Estrada R, Nagore E, et al. Extravasación de agentes citostáticos: Una complicación grave del tratamiento oncológico. Actas Dermosifiliogr. 2006;97(3):169–76.
  • Ojeda S, Martinez C. Afrontamiento de las mujeres diagnosticadas de cáncer de mama. Rev enferm Hered [Internet]. 2012;5(2):89–96. Available from: https://faenf.cayetano.edu.pe/images/pdf/Revistas/2012/febrero/04 CANCER DE MAMA.pdf
  • Leal Torrealba C, Soledad Jiménez Picazo Dirección M. Afrontamiento del cancer de mama. papel de enfermería en el campo de la psicología. 2015;2(77):1–18.
  • Malak, A.T.; Gumus AB. Nursing interventions and factors affecting physical, psychological and social adaptation of women with breast cancer. Asian Pac J Cancer Prev. 2009;10(1):173–6.